Four out of a total of 16 vaccinated patients experienced favourable clinical responses; 4 prostate cancer patients had partial disease resolution, as assessed by serial monitoring of circulating PSA >10% (Table 2). This evidence concerns the gene KLK3 and prostate cancer.